Catalyst Wire Dossier Catalyst Wire Dossier

OCUL101

· Shenzhen Oculgen Biomedical Technology Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OCUL101, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B. [Phase 2, Phase 3]

See pricing